Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Investing Activities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Cash from Investing Activities for 7 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 146.42% to -$1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.7 million, a 4.69% decrease, with the full-year FY2025 number at $30.7 million, down 4.69% from a year prior.
  • Cash from Investing Activities was -$1.0 million for Q4 2025 at Fulcrum Therapeutics, down from $18.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $38.1 million in Q1 2024 to a low of -$106.6 million in Q3 2021.
  • A 5-year average of -$4.5 million and a median of $3.3 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 11561.06% in 2021, then surged 934.58% in 2023.
  • Fulcrum Therapeutics' Cash from Investing Activities stood at -$9.1 million in 2021, then tumbled by 299.85% to -$36.4 million in 2022, then skyrocketed by 150.48% to $18.4 million in 2023, then tumbled by 87.69% to $2.3 million in 2024, then tumbled by 146.42% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Cash from Investing Activities are -$1.0 million (Q4 2025), $18.6 million (Q3 2025), and $13.9 million (Q2 2025).